中国学者近期发表的论文
1.	The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis. Author: Sun Y1, Wang P2, Yang W1, Shan Y1, Zhang Q1, Wu H3. Journal: Cancer Biol Ther. 2019;20(6):729-739. doi: 10.1080/15384047.2018.1529121. Epub 2019 Mar 27.    PubMed      DOI
2.	EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway. Author: Lei T1, Zhu X2, Zhu K2, Jia F1, Li S1. Journal: Cancer Biol Ther. 2019 Mar 31:1-10. doi: 10.1080/15384047.2019.1595276. [Epub ahead of print]    PubMed      DOI
3.	Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Author: Zhu X1, Zhang Q2, Wang D1, Liu C1, Han B2, Yang JM3. Journal: Cancer Biol Ther. 2019 Mar 31:1-8. doi: 10.1080/15384047.2019.1595282. [Epub ahead of print]    PubMed      DOI
4.	Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1. Author: Wang D1, Qian G1, Wang J1, Wang T1, Zhang L1, Yang P1, Lin F1. Journal: Cancer Biol Ther. 2019 Apr 12:1-8. doi: 10.1080/15384047.2019.1591675. [Epub ahead of print]    PubMed      DOI
5.	The LncRNA LINC00963 facilitates osteosarcoma proliferation and invasion by suppressing miR-204-3p/FN1 axis. Author: Zhou Y1, Yin L2, Li H1, Liu LH1, Xiao T1. Journal: Cancer Biol Ther. 2019 Apr 12:1-8. doi: 10.1080/15384047.2019.1598766. [Epub ahead of print]    PubMed      DOI
6.	A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma. Author: Zhang B1, Chen M1, Jiang N1, Shi K1, Qian R1. Journal: Cancer Biol Ther. 2019 Apr 12:1-9. doi: 10.1080/15384047.2019.1598762. [Epub ahead of print]    PubMed      DOI
7.	Knockdown of lncRNA LEF1-AS1 inhibited the progression of oral squamous cell carcinoma (OSCC) via Hippo signaling pathway. Author: Zhang C1, Bao C2, Zhang X2, Lin X2, Pan D1, Chen Y2. Journal: Cancer Biol Ther. 2019 Apr 14:1-10. doi: 10.1080/15384047.2019.1599671. [Epub ahead of print]    PubMed      DOI
8.	Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Author: Jing W1,2, Yan W1,3, Liu Y4, Li J1,3, Yu J1,3, Zhu H1,3. Journal: Cancer Biol Ther. 2019 Apr 14:1-6. doi: 10.1080/15384047.2019.1598760. [Epub ahead of print]    PubMed      DOI
9.	MiR-202-5p/PTEN mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway. Author: Liu T1, Guo J2, Zhang X1. Journal: Cancer Biol Ther. 2019 Apr 14:1-10. doi: 10.1080/15384047.2019.1591674. [Epub ahead of print]    PubMed      DOI
10.	Serum metabolite profiling of familial adenomatous polyposis using ultra performance liquid chromatography and tandem mass spectrometry. Author: Sun L1, Kang Q2, Pan Y2, Li N2, Wang X2, He Y2, Wang H2, Yu D2, Xie H2, Yang L2, Lu Y3, Jin P2, Sheng J1. Journal: Cancer Biol Ther. 2019 Apr 14:1-12. doi: 10.1080/15384047.2019.1595277. [Epub ahead of print]    PubMed      DOI

同类著名期刊名称 h-index CiteScore CA-A CANCER JOURNAL FOR CLINICIANS 144 160.19 Nature Reviews Clinical Oncology 127 8.04 NATURE REVIEWS CANCER 396 23.23 LANCET ONCOLOGY 274 10.07 JOURNAL OF CLINICAL ONCOLOGY 494 11.08 CANCER CELL 295 15.04 ANNALS OF ONCOLOGY 210 8.44 SEMINARS IN CANCER BIOLOGY 134 8.86 CLINICAL CANCER RESEARCH 292 8.32 CANCER RESEARCH 411 6.94

中科院JCR同大类学科的热搜期刊 浏览次数 MEDICINE 286005 CANCER RESEARCH 163640 International Journal of Nanomedicine 162050 Molecular Medicine Reports 161915 CANCER LETTERS 157137 JOURNAL OF ETHNOPHARMACOLOGY 138967 BIOMEDICINE & PHARMACOTHERAPY 136940 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 133576 Theranostics 132879 International Journal of Environmental Research and Public Health 131238